Turnstone Biologics Corp. announced the appointment of industry veteran William Waddill to the Company?s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.

These changes became effective as of April 15, 2024. Mr. Waddill brings more than three decades of financial and operational expertise in the biotechnology space, and proven leadership in industry organizations. Mr. Waddill currently sits on the Boards of Protagonist Therapeutics Inc., Arrowhead Pharmaceuticals, and Annexon Inc., serving as Audit Chair.

He is also an emeritus Board member of the Association of Bioscience Financial Officers (ABFO) and former Chairman of the Biotechnology Industry Organization (BIO) Business Solutions Advisory Board and Finance and Tax Committee. In his most recent operational role, Mr. Waddill served as Senior Vice President (SVP) and Chief Financial Officer (CFO), of Calithera Biosciences Inc., from 2014 to 2016, which he joined from OncoMed Pharmaceuticals Inc., where he also served as SVP and CFO from 2007 to 2014. Prior to this, Mr. Waddill served as SVP and CFO of Ilypsa Inc., between 2006 and 2007, a biotechnology company that was acquired by Amgen Inc., in 2007.

He received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant (inactive), after working at PricewaterhouseCoopers LLP and Deloitte LLP in Boston.